RRML - Beyond PSA: a multi-modal pilot study identifying novel proteomic biomarkers in paraffin-embedded prostate cancer tissue
AMLR

ISSN online: 2284-5623

ISSN-L: 1841-6624

Rejection rate (2020): 75%

Română English


Journal Metrics

Impact Factor 0.5
Five Year Impact Factor 0.5
JCI 0.12


Advanced search


Top 10 downloaded articles
- December 2024 -
 
Biomarkers of acute kidney inj... 6
A comprehensive review of glyc... 6
Investigation of cytokine chan... 6
Validation of GOD / PAP method... 4
Romanian Review of Laboratory ... 4
Towards appropriate training f... 4
Small patients, big challenges... 3
Expressions of vascular endoth... 3
Role of Th1/Th2 imbalance medi... 3
Recomandările naționale ale ... 3

Log in

Concept, Design & Programming
Dr. Adrian Man

   
 
Nr. 32(3)/2024 DOI:10.2478/rrlm-2024-0022
XML
TXT

Research article

Beyond PSA: a multi-modal pilot study identifying novel proteomic biomarkers in paraffin-embedded prostate cancer tissue

Ioan-Bogdan Juravle, Ioana-Ecaterina Pralea, Radu-Cristian Moldovan, Rareș Drula, Nicolae Crișan, Raluca-Maria Bungărdean, Elisabeta-Ioana Hirișcău, Maria Iacobescu, Ximena-Maria Mureșan, Cristina-Adela Iuga

Correspondence should be addressed to: Cristina-Adela Iuga

Abstract:

Background: Prostate cancer (PCa) is a common and complex disease in men, often progressing from localized to aggressive metastatic stages requiring advanced therapies. Early detection of PCa relies primarily on multiparametric tests, with limitations, like over-diagnosis and lack of specificity. Advances in molecular profiling, particularly proteomics, could enhance patient stratification and personalized therapies. Methods: We conducted an analysis using Formalin-Fixed Paraffin-Embedded (FFPE) samples from 23 patients diagnosed with prostatic adenocarcinoma. Proteins were extracted from tissues, followed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis. The data were processed to identify proteins and subsequent bioinformatics analysis was performed to uncover significant pathways and potential biomarkers panel. Validation of identified biomarkers was carried out through Western blotting (WB). Results: Proteomic profiling identified 1,159 proteins, including 176 significantly elevated in tumor tissues. Enrichment analysis highlighted their involvement in stress response, protein metabolism, and signaling pathways associated with PCa progression. Key pathways included mTORC1 signaling, Myc signaling, and focal adhesion. A biomarker panel consisting of KLK3, GDF15, MIF, and AZGP1 was proposed based on their discriminatory power in distinguishing tumor from normal tissues. WB confirmed the tumor-specific expression of these candidates, particularly GDF15 and KLK3. Conclusions: The present study shows for the first time a multi-modal approach that combines a panel of PCa tissue proteins, as a new tool of PCa in patients. The identified biomarker panel offers promise for improving detection and tailoring personalized treatment strategies in PCa management. Further validation in larger cohorts and clinical settings is warranted to establish these findings.

Keywords: biomarker panel, FFPE tissue, prostate cancer, proteomics

Received: 10.6.2024
Accepted: 9.7.2024
Published: 26.7.2024

 
  PDF Download full text PDF
(2704 KB)
     
 
How to cite
Juravle IB, Pralea IE, Moldovan RC, Drula R, Crișan N, Bungărdean RM, et al. Beyond PSA: a multi-modal pilot study identifying novel proteomic biomarkers in paraffin-embedded prostate cancer tissue. Rev Romana Med Lab. 2024;32(3):219-28. DOI:10.2478/rrlm-2024-0022